{"slideshow_credits": null, "snippet": "The implied market value of the merged company is about $750 million.", "abstract": "Tekmira Pharmaceuticals Corporation agrees to buy OnCore Biopharma for about $750 million, to develop hepatitis B virus drugs.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [], "organization": "REUTERS", "original": "By REUTERS", "contributor": ""}, "web_url": "http://www.nytimes.com/2015/01/13/business/dealbook/tekmira-to-buy-oncore-and-develop-hepatitis-b-drugs.html", "lead_paragraph": "The implied market value of the merged company is about $750 million.", "headline": {"print_headline": "Tekmira to Buy OnCore and Develop Hepatitis B Drugs", "main": "Tekmira to Buy Oncore and Develop Hepatitis B Drugs", "content_kicker": "Business Briefing", "kicker": "Business Briefing"}, "_id": "54b4624d38f0d8623a353f6c", "word_count": "126", "multimedia": [], "pub_date": "2015-01-13T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Tekmira Pharmaceuticals Corporation", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "OnCore Biopharma Inc", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Hepatitis", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "5"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "Brief"}